13750-63-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-METHYLTHIAZOL-2-YL)METHANOL is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of diverse molecules with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical industry, (4-METHYLTHIAZOL-2-YL)METHANOL serves as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in protecting crops and controlling pests.
Used as an Antimicrobial Agent:
(4-METHYLTHIAZOL-2-YL)METHANOL is used as an antimicrobial agent due to its ability to inhibit the growth of microorganisms. This property makes it a potential candidate for use in various applications, such as in the development of antimicrobial coatings or in the preservation of perishable goods.
Used as a Food Preservative:
Owing to its antimicrobial properties, (4-METHYLTHIAZOL-2-YL)METHANOL has been studied for its potential use as a food preservative. It can help extend the shelf life of food products by inhibiting the growth of spoilage-causing microorganisms, thereby maintaining the quality and safety of the food.
Used in Organic Synthesis:
(4-METHYLTHIAZOL-2-YL)METHANOL is utilized as an intermediate in organic synthesis for the production of various organic compounds. Its unique structure allows for the formation of a wide range of molecules, making it a valuable component in the synthesis of specialty chemicals and other organic products.

InChI:InChI=1/C5H7NOS/c1-4-3-8-5(2-7)6-4/h3,7H,2H2,1H3

Upstream product

• 50-00-0 formaldehyd 
• 89602-38-0 4-methyl-thiazole-2-yllithium 
• 13750-68-0 4-methyl-thiazole-2-carbaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 693-95-8 4-Methylthiazole 
• 7210-73-3 4-Methylthiazol-2-carbonsaeure-ethylester 

Downstream Products

• 50398-72-6 2-(chloromethyl)-4-methylthiazole 
• 82294-70-0 4-methyl-1,3-thiazole-5-carbaldehyde 
• 1173897-87-4 (5-bromo-4-methyl-1,3-thiazol-2-yl)methanol 
• 1459695-42-1 C₃₂H₃₂F₅N₃O₂S 
• 1459695-41-0 C₂₅H₂₉F₂N₃O₂S 
• 1459695-61-4 C₁₅H₁₈ClNS 
• 1459695-60-3 C₁₅H₁₉NOS 
• 1459695-28-3 C₂₉H₃₅F₂N₃O₂S 
• 1459695-62-5 C₂₂H₂₂F₂N₂O₂S 
• 1459695-08-9 C₂₀H₂₀F₂N₄O₂S 
• 1459695-56-7 C₁₇H₁₃F₂N₃O₂S 
• 1459695-53-4 C₁₅H₁₇F₂N₃O₂S 
• 1459695-72-7 C₁₉H₁₃F₅N₂O₂S 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists

G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders. During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)?=?75?nM, maximal response (Emax)?=?122%) starting from a high-throughput screening hit 3 (EC50?=?470?nM, Emax?=?56%). The structural features of a reported GPR52 agonist were applied to 3, led to design 4-azolylbenzamides as novel GPR52 agonists. A structure–activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole derivative 4u, which demonstrated excellent bioavailability in rats (F?=?53.8%). Oral administration of 4u (10?mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice. Thus, 4u is a promising lead compound for drug discovery research of GPR52 agonists.

ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES

Disclosed are a fused pyrimidine derivative of formula (I), and a pharmaceutically acceptable salt, stereoisomer, hydrate and solvate thereof, which have an excellent inhibitory activity on FMS kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating diseases caused by abnormal activation of FMS kinases such as immunologic diseases, metabolic diseases, inflammatory diseases, cancers and tumors.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

ANTIMICROBIAL AGENTS

The invention provides compounds of formual (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.